Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Mallinckrodt
Merck
Moodys

Last Updated: September 25, 2022

JORNAY PM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Jornay Pm, and what generic alternatives are available?

Jornay Pm is a drug marketed by Ironshore Pharms and is included in one NDA. There are fifteen patents protecting this drug.

This drug has thirty-three patent family members in fourteen countries.

The generic ingredient in JORNAY PM is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for JORNAY PM
International Patents:33
US Patents:15
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for JORNAY PM
What excipients (inactive ingredients) are in JORNAY PM?JORNAY PM excipients list
DailyMed Link:JORNAY PM at DailyMed
Drug patent expirations by year for JORNAY PM
Drug Prices for JORNAY PM

See drug prices for JORNAY PM

US Patents and Regulatory Information for JORNAY PM

JORNAY PM is protected by fifteen US patents.

Patents protecting JORNAY PM

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods and compositions for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions for treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treatment of attention deficit hyperactivity disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-005 Aug 8, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-003 Aug 8, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-003 Aug 8, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-004 Aug 8, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JORNAY PM

See the table below for patents covering JORNAY PM around the world.

Country Patent Number Title Estimated Expiration
Japan 2017128614 注意欠陥障害の処置のための方法および組成物 (METHODS AND COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT DISORDER) See Plans and Pricing
Japan 2018197276 注意欠陥障害の処置のための方法および組成物 (METHODS AND COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT DISORDER) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2012129551 See Plans and Pricing
Australia 2018202002 METHODS AND COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT DISORDER See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
AstraZeneca
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.